Silverarc Capital Management’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-643,636
| Closed | -$30.6M | – | 69 |
|
|
2025
Q3 | $30.6M | Sell |
643,636
-70,175
| -10% | -$3.4M | 4.12% | 6 |
|
|
2025
Q2 | $38.1M | Sell |
713,811
-6,181
| -0.9% | -$281K | 7.02% | 2 |
|
|
2025
Q1 | $29.1M | Sell |
719,992
-19,571
| -3% | -$830K | 5.96% | 4 |
|
|
2024
Q4 | $20.6M | Buy |
739,563
+99,723
| +16% | +$3.02M | 4.5% | 5 |
|
|
2024
Q3 | $18.4M | Buy |
639,840
+14,753
| +2% | +$385K | 4.12% | 6 |
|
|
2024
Q2 | $14.7M | Buy |
625,087
+225,138
| +56% | +$4.81M | 3.46% | 8 |
|
|
2024
Q1 | $10.1M | Buy |
399,949
+150,695
| +60% | +$3.62M | 2.81% | 12 |
|
|
2023
Q4 | $5.82M | Buy |
249,254
+217,918
| +695% | +$4.3M | 1.73% | 19 |
|
|
2023
Q3 | $1.58M | Sell |
31,336
-210,021
| -87% | -$9.78M | 0.48% | 51 |
|
|
2023
Q2 | $11.3M | Buy |
241,357
+38,796
| +19% | +$1.78M | 3.49% | 7 |
|
|
2023
Q1 | $7.75M | Buy |
202,561
+30,461
| +18% | +$1.36M | 3.2% | 7 |
|
|
2022
Q4 | $9.43M | Sell |
172,100
-127,900
| -43% | -$5.48M | 2.7% | 7 |
|
|
2022
Q3 | $10.2M | Buy |
300,000
+39,675
| +15% | +$607K | 3.46% | 5 |
|
|
2022
Q2 | $2.46M | Buy |
+260,325
| New | +$2.71M | 0.76% | 36 |
|
|
2021
Q3 | – | Sell |
-33,028
| Closed | -$819K | – | 83 |
|
|
2021
Q2 | $819K | Buy |
33,028
+1,028
| +3% | +$28.9K | 0.37% | 69 |
|
|
2021
Q1 | $928K | Sell |
32,000
-3,179
| -9% | -$96.2K | 0.51% | 55 |
|
|
2020
Q4 | $908K | Buy |
+35,179
| New | +$979K | 0.53% | 52 |
|
Other funds holding AKRO
Silverarc Capital Management's AKRO Position: Q4 2025 in Review
Silverarc Capital Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 643,636 shares — an estimated $30.6M sold.
Silverarc Capital Management first reported a position in AKRO in Q4 2020 and held it in 17 quarters. The position peaked at $38.1M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Silverarc Capital Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Silverarc Capital Management sold 643,636 Akero Therapeutics shares in Q4 2025, an estimated $30.6M.
- Silverarc Capital Management first reported a position in Akero Therapeutics in Q4 2020 and held it in 17 quarters.
- Silverarc Capital Management's Akero Therapeutics position peaked at $38.1M in Q2 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Silverarc Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.